Clinical Trials Logo

Filter by:
NCT ID: NCT04551352 Completed - Uveal Melanoma Clinical Trials

A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

Start date: October 28, 2020
Phase: Phase 1
Study type: Interventional

This is a first-in-human, multi-center clinical study to determine the safety, Maximum Tolerated Dose (MTD) and/or Optimal Biological Dose (OBD) as well as the optimal schedule for intravenous (IV) and/or subcutaneous (SC) administrations of RO7293583 with or without obinutuzumab pretreatment, in participants with unresectable metastatic TYRP1-positive melanomas who have progressed on standard of care (SOC) treatment, are intolerant to SOC, or are non-amenable to SOC. This study will include an initial single participant dose-escalation part one followed by a multiple participant dose-escalation part two with the possibility of expansion.

NCT ID: NCT04550208 Completed - Clinical trials for Landing Biomechanics

Biomechanical Analysis of Different Landing Manoevres

Start date: August 24, 2020
Phase:
Study type: Observational

In this study, three-dimensional biomechanics , by means of lower limb joint angles and moments (opto-electronic system with synchronised force plate), of different landing manoevres will be compared in a population of basketball and volleyball players.

NCT ID: NCT04546425 Completed - Clinical trials for Pneumococcal Disease

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants

Start date: September 9, 2020
Phase: Phase 3
Study type: Interventional

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants

NCT ID: NCT04544787 Completed - Poliomyelitis Clinical Trials

A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates

Start date: October 22, 2018
Phase: Phase 2
Study type: Interventional

This study is designed to evaluate the safety and immunogenicity of two novel type 2 oral poliovirus vaccine (nOPV2) candidates (nOPV2 candidate 1 and nOPV2 candidate 2) in adults. The primary objectives of the study include the general safety and immunogenicity of the two candidate vaccines in healthy volunteers previously vaccinated with Sabin monovalent OPV or inactivated polio vaccine (IPV) only.

NCT ID: NCT04544280 Completed - Stroke Clinical Trials

Effect of Repeated Injections of Higher Doses of Botulinum Toxin on Lower Limb of Spastic Hemiplegic Patients on Gait.

Start date: September 13, 2018
Phase: N/A
Study type: Interventional

1. To show that repeated injections of higher doses of botulinum toxin are significantly more effective than the injection of unique, lower doses, on gait function. 2. To describe the effect of repeated injections of botulinum toxin on the muscle structure in terms of volume, fat accumulation and fibrosis, by means of MRI studies

NCT ID: NCT04543344 Completed - Healthy Clinical Trials

Study To Evaluate The Pharmacokinetic, Safety And Tolerability Of Single Or Multiple Subcutaneous Doses of Recifercept

Start date: September 17, 2020
Phase: Phase 1
Study type: Interventional

This will be a single center, randomized, parallel group, repeated dose study of recifercept (Cohort 1 and Cohort 2) or placebo (only in Cohort 1) in approximately 18 healthy participants, using 2 cohorts (N = 9) at two dose levels of recifercept.

NCT ID: NCT04542070 Completed - HIV Infections Clinical Trials

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed

SOLAR
Start date: November 9, 2020
Phase: Phase 3
Study type: Interventional

This study is designed to assess the antiviral activity and safety of a two-drug regimen of CAB LA + RPV LA compared with maintenance of BIK. BIKTARVY is a registered trademark of Gilead Sciences.

NCT ID: NCT04542057 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD

Start date: September 22, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if ensifentrine is safe and effective for the treatment of patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).

NCT ID: NCT04541615 Completed - Surgery Clinical Trials

Orsi Surgical Skills E-learning Trial

OSSET
Start date: August 25, 2020
Phase: N/A
Study type: Interventional

The training of robotic surgical procedural skills has been challenged by changes in work practices and safety concerns specifically related to training. In surgery and procedural medicine simulation-based training has been demonstrated to supplant the early part of the learning curve. Training in the skills laboratory is however expensive because of equipment and supervision burdens. In this study the investigators will assess the economic impact of proficiency-based progression (PBP) e-learning training prior to training in the skills laboratory. 48 trainees will be randomly assigned to one of four groups. 1) will receive an apprenticeship type training (Group 1 ; n=12), 2) A standard or traditional trained group (Group 2; n=12) will then receive face-to-face lectures on how to perform the robotic surgical training task (i.e., ORSI chicken anastomosis task for learning robotic suturing and knot tying.) 3) The third group (Group 3; n=12) will have e-learning training prior to training in the skills laboratory and then learn the same task. 4) The fourth group (Group 4; n=12) will have the exact same pre-course e-learning curriculum as Group 3 but will be required to study it until they score at the quantitatively defined proficiency benchmark of experienced robotic surgeons, i.e., the mean performance level of experienced robotic surgeons - they can complete the task with <10 performance errors. The research will be conducted at the laboratory skills lab of Orsi Academy, Proefhoevestraat 12 9090 Melle. It will be conducted by Maxime Lasseel and Laura Langhendries, under direct guidance of Dr. S. Puliatti, Prof. A.G. Gallagher and Prof. A. Mottrie.

NCT ID: NCT04540744 Completed - Healthy Clinical Trials

A Study of Macitentan/Tadalafil Combination Administered a Fixed-dose Combination Formulation Compared to the Reference Free Combination of Macitentan and Tadalafil

Start date: April 30, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the rate and extent of absorption of macitentan and tadalafil following administration of a single oral dose of a fixed-dose combination (FDC) of 10 milligram (mg)/20 mg macitentan/tadalafil (test), compared to the coadministration as a free combination (reference) of 10 mg macitentan and 20 mg tadalafil under fasted conditions in healthy adult participants.